There are two trials that I think are probably the most excited about. One of them is called the PEAK trial, and it was a ...
George: The phase 1/2 study is evaluating a new compound called DCC-3009. It is a drug that was designed specifically to work ...
A young woman was diagnosed with a rare stomach cancer just months after doctors shrugged off her symptoms as being 'women's ...
Traditionally, cancer diagnosis and prognosis rely heavily on histopathological examination, where tissue morphology is evaluated under the microscope. However, the molecular ...
Life is often a one-shot performance. For Corning’s Jeff Cortright he’s making the most of every last shot he is given. A ...
NDA submissions for bezuclastinib in Gastrointestinal Stromal Tumors (GIST) and Advanced Systemic Mastocytosis (AdvSM) are on-track for the first half of 2026 based on the strength of clinical results ...
A live webcast will be available on the Investors & Media page of Cogent’s website at investors.cogentbio.com. A replay of the webcast will be available approximately two hours after the completion of ...
1don MSN
Doctors dismissed 25-year-old's symptoms as 'women's problems' then she was diagnosed with cancer
A young woman was diagnosed with a rare stomach cancer just months after doctors shrugged off her symptoms as being 'women's ...
Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined ...
A personal reflection on the promise and limits of CAR T therapy—its breakthroughs, failures, scientific bottlenecks, and what must change to truly save more lives.
Inflammation covertly rewires the bone marrow, enabling mutated stem cells to rise and setting the stage for future blood disease.
Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback